

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6062722

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICIUS HENDRIKUS CORNELIS VAN BERKEL	07/30/2018
FRANCESCA ZAMMARCHI	07/18/2018
LISA SKELTON	07/18/2018
RECEIVING PARTY DATA	
Name:	ADC THERAPEUTICS (UK) LIMITED
Street Address:	GEORGE STREET
Internal Address:	4TH FLOOR READING BRIDGE HOUSE
City:	READING, BERKSHIRE
State/Country:	UNITED KINGDOM
Postal Code:	RG1 8LS
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16605708
CORRESPONDENCE DATA	
Fax Number:	(608)662-1276
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6086621277
Email:	maschur@casimirjones.com
Correspondent Name:	MELISSA E. KOLOM
Address Line 1:	2275 DEMING WAY
Address Line 2:	SUITE #310
Address Line 4:	MIDDLETON, WISCONSIN 53562
ATTORNEY DOCKET NUMBER:	MEWB-38012.251
NAME OF SUBMITTER:	MELISSA E. KOLOM
SIGNATURE:	/Melissa E. Kolom/
DATE SIGNED:	04/15/2020
Total Attachments: 14	
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page1.tif	
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page2.tif	

source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page3.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page4.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page5.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page6.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page7.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page8.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page9.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page10.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page11.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page12.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page13.tif
source=Assignment-PHCVB-FZ-ADCTUK-ADCT-MEDIMMUNE#page14.tif

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties

- (1) VAN BERKEL, PATRICIUS HENDRIKUS CORNELIS c/o ADC Therapeutics (UK) Limited, 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS;
 - (2) ZAMMARCHI, FRANCESCA c/o ADC Therapeutics (UK) Limited, 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS;
 - (3) SKELTON, USA c/o ADC Therapeutics (UK) Limited, 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS;
- each an "Inventor" or together the "Inventors" as the context may indicate;
- (4) ADC THERAPEUTICS (UK) LIMITED incorporated and registered in England & Wales with company number 09353055 whose registered office is at 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS ("ADCT UK");
 - (5) ADC THERAPEUTICS SA incorporated and registered in the Swiss Confederation and whose principal address is Route de la Corniche 3b, 1066 Epalinges, Switzerland ("ADCT SA"); and
 - (6) MEDIMMUNE LIMITED incorporated and registered in England & Wales with company number 02451177 whose registered office address is at Milstein Building, Grants Park, Cambridge, CB21 6GH ("Medimmune").

Agreed terms

1. Definitions

The definitions in this clause apply in this Assignment.

"Completion Applications" means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

"Invention" means the inventions entitled COMBINATION THERAPY, being the subject matter of the Priority Applications.

"Patent Applications" means the Priority Applications, the Completion Applications and any future applications linked by one or more priorities to the Priority Applications or the Completion Applications and all matter contained in such applications and any and all;

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

"Priority Applications" means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

2. Assignment

In consideration of the sum of £1 (sufficiency and receipt of which the Inventors, ADCT UK and ADCT SA each expressly acknowledge), each of the Inventors hereby assigns absolutely to ADCT UK all its right, title and interest, thereafter ADCT UK hereby assigns absolutely to ADCT SA all its right, title and interest, and thereafter ADCT SA hereby assigns absolutely to Medimmune a one half share in all its right, title and interest in all countries, regions and territories of the world in, to and arising from the invention, and with effect from immediately prior to the filing of each, the Patent Applications, to the effect that all patents granted therefrom shall vest in and shall proceed jointly in the names of ADCT SA and Medimmune, and including (but not limited to):

- (a) in respect of the invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
 - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
 - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. Further assurance

The Inventors, ADCT UK and ADCT SA shall, at ADCT SA's and Medimmune's joint cost, perform all further acts and things, and execute all further documents, required by law or which ADCT SA or Medimmune requests to vest in ADCT SA or Medimmune the full benefit

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

of the right, title and interest assigned to ADCT SA and Medimmune under this Assignment,
including (but not limited to):

- (a) documents required to be signed by or on behalf of the Inventors, ADCT UK or ADCT SA in the course of any applications which relate to the invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of ADCT SA or Medimmune as co-applicant for, or co-proprietor of, the Patent Applications; and
- (c) assisting ADCT SA or Medimmune in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against ADCT SA or Medimmune by any third party or in the resolution of any question concerning the invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. Right to amend the Schedule

The Inventors, ADCT UK, ADCT SA and Medimmune grant the firm of Mewburn Ellis LLP the right to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

5. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

6. Governing law and jurisdiction

This Assignment is governed by the laws of England and Wales and subject to the exclusive jurisdiction of its courts.

Schedule: The Patent Applications

Part 1: Priority Applications

Country	Application No.	Application Date	Title
GB	1706261.3	20 April 2017	COMBINATION THERAPY
GB	1706260.5	20 April 2017	COMBINATION THERAPY
GB	1706259.7	20 April 2017	COMBINATION THERAPY

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 85 WO

GB	1706258.9	20 April 2017	COMBINATION THERAPY
GB	1706257.1	20 April 2017	COMBINATION THERAPY
GB	1706256.3	20 April 2017	COMBINATION THERAPY
GB	1706254.8	20 April 2017	COMBINATION THERAPY
GB	1705253.0	20 April 2017	COMBINATION THERAPY
GB	1706252.2	20 April 2017	COMBINATION THERAPY
GB	1706251.4	20 April 2017	COMBINATION THERAPY
GB	1706250.6	20 April 2017	COMBINATION THERAPY
GB	1706249.8	20 April 2017	COMBINATION THERAPY
GB	1706248.0	20 April 2017	COMBINATION THERAPY
GB	1706247.2	20 April 2017	COMBINATION THERAPY
GB	1706246.4	20 April 2017	COMBINATION THERAPY
GB	1706245.6	20 April 2017	COMBINATION THERAPY
GB	1706231.6	20 April 2017	COMBINATION THERAPY
GB	1705230.8	20 April 2017	COMBINATION THERAPY
GB	1706229.0	20 April 2017	COMBINATION THERAPY
GB	1706228.2	20 April 2017	COMBINATION THERAPY
GB	1706227.4	20 April 2017	COMBINATION THERAPY
GB	1706226.6	20 April 2017	COMBINATION THERAPY
GB	1706225.8	20 April 2017	COMBINATION THERAPY
GB	1706224.1	20 April 2017	COMBINATION THERAPY
GB	1706223.3	20 April 2017	COMBINATION THERAPY
GB	1706237.3	20 April 2017	COMBINATION THERAPY
GB	1706236.5	20 April 2017	COMBINATION THERAPY
GB	1706235.7	20 April 2017	COMBINATION THERAPY
GB	1706234.0	20 April 2017	COMBINATION THERAPY
GB	1706233.2	20 April 2017	COMBINATION THERAPY
GB	1706221.7	20 April 2017	COMBINATION THERAPY
GB	1706232.4	20 April 2017	COMBINATION THERAPY
GB	1802947.0	23 February 2018	COMBINATION THERAPY
GB	1805189.6	29 March 2018	COMBINATION THERAPY
GB	1805660.6	05 April 2018	COMBINATION THERAPY

Part 2: Completion Applications

Country/region	Application No.	Application Date	Title
WO	PCT/EP2018/060215	20 April 2018	COMBINATION THERAPY

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

WO	PCT/EP2018/060214	20 April 2018	COMBINATION THERAPY
WO	PCT/EP2018/060209	20 April 2018	COMBINATION THERAPY
WO	PCT/EP2018/060210	20 April 2018	COMBINATION THERAPY

Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of
clause 2 of this Assignment

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351501, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 72 - 95 WO, Patent 80 - 86 WO

Executed by PATRICIUS HENDRIKUS
CORNELIS VAN BERKEL in the presence of:


SIGNATURE OF WITNESS

NAME: C.v. Berkel


ADDRESS: Neerdyck 3, 3601 C2 Maarssen, NL

OCCUPATION: Owner & signatory

DATE: 30 Jul - 2018


SIGNATURE

Executed by FRANCESCA ZAMMARCHI in
the presence of:



SIGNATURE OF WITNESS

NAME: LISA SKELTON


ADDRESS: 4 HAREFIELD ROAD, RICKMANSDEN WD3 1LU

OCCUPATION: PROJECT MANAGER

DATE: 18/07/2018


SIGNATURE

Executed by LISA SKELTON in the
presence of:



SIGNATURE OF WITNESS

NAME: FRANCESCA ZAMMARCHI


ADDRESS: 32 WARWICK ROAD W15 3FJ

OCCUPATION: CANCER BIOLOGIST

DATE: 18 July 2018


SIGNATURE

Executed by ADC THERAPEUTICS (UK) Ltd.
acting by Michael Forer, an Authorised
Signatory, in the presence of:


SIGNATURE OF WITNESS


NAME: Dulce Gonçalves

ADDRESS: Biopôle, Route de la Corniche

36, 1066 Epalinges, Switzerland


OCCUPATION: General Counsel

DATE: 16 July 2018


SIGNATURE

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/EP7351844, RKA/EP7351851, RAK/EP7351901, RKA/EP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

Executed by ADC THERAPEUTICS SA acting
by Michael Forer, an Authorised Signatory,
in the presence of:



SIGNATURE

SIGNATURE OF WITNESS

NAME: Dulce Goncalves
ADDRESS: Biopôle, Route de la Corniche
3B, 1066 Epalinges, Switzerland
OCCUPATION: General Counsel
DATE: 16 July 2018

Executed by MEDIMMUNE LIMITED acting
by Christopher S Winter, an Authorised
Signatory, in the presence of:

SIGNATURE

SIGNATURE OF WITNESS

NAME:
ADDRESS:
OCCUPATION:
DATE:

ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties

- (1) **VAN BERKEL, PATRICIUS HENDRIKUS CORNELIS** c/o ADC Therapeutics (UK) Limited, 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS;
- (2) **ZAMMARCHI, FRANCESCA** c/o ADC Therapeutics (UK) Limited, 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS;
- (3) **SKELTON, LISA** c/o ADC Therapeutics (UK) Limited, 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS;

each an "Inventor" or together the "Inventors" as the context may indicate;

- (4) **ADC THERAPEUTICS (UK) LIMITED** incorporated and registered in England & Wales with company number 09353055 whose registered office is at 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS ("ADCT UK");
- (5) **ADC THERAPEUTICS SA** incorporated and registered in the Swiss Confederation and whose principal address is Route de la Corniche 3b, 1066 Epalinges, Switzerland ("ADCT SA"); and
- (6) **MEDIMMUNE LIMITED** incorporated and registered in England & Wales with company number 02451177 whose registered office address is at Milstein Building, Granta Park, Cambridge, CB21 6GH ("MedImmune").

Agreed terms

1. Definitions

The definitions in this clause apply in this Assignment.

"Completion Applications" means the completion patent applications, short particulars of which are set out in Part 2 of the Schedule.

"Invention" means the inventions entitled COMBINATION THERAPY, being the subject matter of the Priority Applications.

"Patent Applications" means the Priority Applications, the Completion Applications and any future applications linked by one or more priorities to the Priority Applications or the Completion Applications and all matter contained in such applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

“Priority Applications” means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

2. Assignment

In consideration of the sum of £1 (sufficiency and receipt of which the Inventors, ADCT UK and ADCT SA each expressly acknowledge), each of the Inventors hereby assigns absolutely to ADCT UK all its right, title and interest, thereafter ADCT UK hereby assigns absolutely to ADCT SA all its right, title and interest, and thereafter ADCT SA hereby assigns absolutely to MedImmune a one half share in all its right, title and interest in all countries, regions and territories of the world in, to and arising from the Invention, and with effect from immediately prior to the filing of each, the Patent Applications, to the effect that all patents granted therefrom shall vest in and shall proceed jointly in the names of ADCT SA and MedImmune, and including (but not limited to):

- (a) in respect of the Invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
 - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
 - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. Further assurance

The Inventors, ADCT UK and ADCT SA shall, at ADCT SA's and MedImmune's joint cost, perform all further acts and things, and execute all further documents, required by law or which ADCT SA or MedImmune requests to vest in ADCT SA or MedImmune the full benefit

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

of the right, title and interest assigned to ADCT SA and MedImmune under this Assignment,
including (but not limited to):

- (a) documents required to be signed by or on behalf of the Inventors, ADCT UK or ADCT SA in the course of any applications which relate to the Invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of ADCT SA or MedImmune as co-applicant for, or co-proprietor of, the Patent Applications; and
- (c) assisting ADCT SA or MedImmune in obtaining, defending and enforcing any of the Patent Applications, and assisting with any other proceedings which may be brought by or against ADCT SA or MedImmune by any third party or in the resolution of any question concerning the Invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. Right to amend the Schedule

The Inventors, ADCT UK, ADCT SA and MedImmune grant the firm of Mewburn Ellis LLP the right to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

5. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

6. Governing law and jurisdiction

This Assignment is governed by the laws of England and Wales and subject to the exclusive jurisdiction of its courts.

Schedule: The Patent Applications

Part 1: Priority Applications

Country	Application No.	Application Date	Title
GB	1706261.3	20 April 2017	COMBINATION THERAPY
GB	1706260.5	20 April 2017	COMBINATION THERAPY
GB	1706259.7	20 April 2017	COMBINATION THERAPY

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

GB	1706258.9	20 April 2017	COMBINATION THERAPY
GB	1706257.1	20 April 2017	COMBINATION THERAPY
GB	1706256.3	20 April 2017	COMBINATION THERAPY
GB	1706254.8	20 April 2017	COMBINATION THERAPY
GB	1706253.0	20 April 2017	COMBINATION THERAPY
GB	1706252.2	20 April 2017	COMBINATION THERAPY
GB	1706251.4	20 April 2017	COMBINATION THERAPY
GB	1706250.6	20 April 2017	COMBINATION THERAPY
GB	1706249.8	20 April 2017	COMBINATION THERAPY
GB	1706248.0	20 April 2017	COMBINATION THERAPY
GB	1706247.2	20 April 2017	COMBINATION THERAPY
GB	1706246.4	20 April 2017	COMBINATION THERAPY
GB	1706245.6	20 April 2017	COMBINATION THERAPY
GB	1706231.6	20 April 2017	COMBINATION THERAPY
GB	1706230.8	20 April 2017	COMBINATION THERAPY
GB	1706229.0	20 April 2017	COMBINATION THERAPY
GB	1706228.2	20 April 2017	COMBINATION THERAPY
GB	1706227.4	20 April 2017	COMBINATION THERAPY
GB	1706226.6	20 April 2017	COMBINATION THERAPY
GB	1706225.8	20 April 2017	COMBINATION THERAPY
GB	1706224.1	20 April 2017	COMBINATION THERAPY
GB	1706223.3	20 April 2017	COMBINATION THERAPY
GB	1706237.3	20 April 2017	COMBINATION THERAPY
GB	1706236.5	20 April 2017	COMBINATION THERAPY
GB	1706235.7	20 April 2017	COMBINATION THERAPY
GB	1706234.0	20 April 2017	COMBINATION THERAPY
GB	1706233.2	20 April 2017	COMBINATION THERAPY
GB	1706221.7	20 April 2017	COMBINATION THERAPY
GB	1706232.4	20 April 2017	COMBINATION THERAPY
GB	1802947.0	23 February 2018	COMBINATION THERAPY
GB	1805189.6	29 March 2018	COMBINATION THERAPY
GB	1805660.6	05 April 2018	COMBINATION THERAPY

Part 2: Completion Applications

Country/region	Application No.	Application Date	Title
WO	PCT/EP2018/060215	20 April 2018	COMBINATION THERAPY

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

WO	PCT/EP2018/060214	20 April 2018	COMBINATION THERAPY
WO	PCT/EP2018/060209	20 April 2018	COMBINATION THERAPY
WO	PCT/EP2018/060210	20 April 2018	COMBINATION THERAPY

Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

Executed by **PATRICIUS HENDRIKUS**
CORNELIS VAN BERKEL in the presence of:

SIGNATURE

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **FRANCESCA ZAMMARCHI** in
the presence of:

SIGNATURE

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **LISA SKELTON** in the
presence of:

SIGNATURE

SIGNATURE OF WITNESS

NAME:

ADDRESS:

OCCUPATION:

DATE:

Executed by **ADC THERAPEUTICS UK**
acting by Michael Forer, an Authorised
Signatory, in the presence of:

SIGNATURE

SIGNATURE OF WITNESS

NAME: Dulce Goncalves

ADDRESS: Biopôle, Route de la Corniche
3B, 1066 Epalinges, Switzerland

OCCUPATION: General Counsel

DATE:

Assignment of invention and PCT/EP2018/060215, PCT/EP2018/060214, PCT/EP2018/060209,
PCT/EP2018/060210
RKA/FP7351844, RKA/FP7351851, RAK/FP7351901, RKA/FP7351893 & Patent 56 - 63 & 103 WO,
Patent 64 - 71 WO, Patent 87 - 95 WO, Patent 80 - 86 WO

Executed by **ADC THERAPEUTICS SA** acting
by Michael Forer, an Authorised Signatory,
in the presence of:

SIGNATURE

SIGNATURE OF WITNESS

NAME: Dulce Goncalves

ADDRESS: Biopôle, Route de la Corniche

3B, 1066 Epalinges, Switzerland

OCCUPATION: General Counsel

DATE:

Executed by **MEDIMMUNE LIMITED** acting
by Christopher S Winter, an Authorised
Signatory, in the presence of:



SIGNATURE



SIGNATURE OF WITNESS

NAME: BARBARA INCE

ADDRESS: MILSTEIN BUILDING, GRANTA PARK, CAMBRIDGE, CB21 6QH

OCCUPATION: PERSONAL ASSISTANT

DATE: 9th JANUARY 2019